The company has given families nationwide access to $33 million in benefits, covering out-of-pocket costs for care from hospital stays to chronic conditions

COLUMBUS, Ohio, July 28, 2026 — Healia, a Columbus-based company that reduces health benefit costs for dual-income families and employers, today announced $18 million in funding, including a $14M Series A led by 111° West Capital, with participation from Y Combinator, First Round Capital, Pioneer Fund, GoAhead Ventures, and North Coast Ventures. To date, Healia has enabled employers to provide $33 million in additional coverage for families nationwide, equipping families to make healthcare’s most consequential decisions as one household, with the full picture in view.

Roughly 30 million American dual-income families are underserved by a healthcare system designed for the 1960s household: one breadwinner, one plan, a spouse at home. Most of those families now have access to two employer plans, and the system quietly overcharges them for having both. That’s because employers pay to cover working spouses who already have coverage elsewhere, and families default to the plan they know because comparing two plans across two enrollment portals is a headache no one is set up to solve.

Healia is a healthcare benefits platform built for dual-income families. Healia’s Total Care Option (TCO) enables employers to pay a family’s out-of-pocket costs and premiums when they enroll in a spouse’s health plan instead of the company’s. Families pay little to nothing for their healthcare, and employers cut their spend significantly.

Here’s how the Total Care Option works:

• Healia compares the family’s health plan options: It prices every path, staying on separate plans or moving to the spouse’s plan with the TCO, and identifies the least expensive choice for the household.
• Families enroll in a spouse’s plan and the TCO: When a family enrolls in their spouse’s plan, they also receive the TCO to help reimburse essential medical expenses.
• Healia manages the entire claims process: When the family incurs copays, coinsurance, deductibles, or premiums on the spouse’s plan, the employer reimburses them through Healia in a matter of hours.

“Healia saved us thousands during the most stressful year of our lives. When my husband’s company implemented Healia, the decision support tool made it a no-brainer: we enrolled in the Total Care Option and added him to my employer’s plan. We found out we were pregnant on New Year’s Day, and between our daughter’s birth and my own cancer diagnosis that year, we submitted a lot of claims. Often we’d get reimbursed before the provider bill even arrived. Our friends and family were shocked. Honestly, so were we,” said one early Healia member in Phoenix, Arizona.

The result is a rare win-win in employer-sponsored healthcare. A family expecting a baby, managing a diagnosis, or living with a chronic condition pays little to nothing out of pocket, saving up to $26,000 a year. Employers are able to provide meaningful benefits that retain and recruit employees while lowering their healthcare costs up to 76% per enrolled household annually.

“In 5 years, picking a health plan will work the way it should have all along. Every family will see both plans side by side, know exactly what each one costs them, and get paid back for choosing well. When 30 million households make that decision with full information, the whole market has to respond. Plans will compete for families instead of families accepting the status quo,” said Priyang Shah, founder and CEO of Healia.

“Millions of dual-income families are paying twice for healthcare coverage they don’t need, yet the employer healthcare system has largely ignored the problem. I spent more than a decade in healthcare operations, including co-founding TigerConnect, so I recognize structural inefficiencies when I see them. This is one of the clearest I’ve encountered. Priyang combines the product vision, operational discipline, and execution capabilities needed to solve it at scale and deliver meaningful savings for working families” said Andrew Brooks, M.D., Co-Founder and Managing Partner at 111° West Capital.

Healia will use the funding to build its next generation of leaders across sales, engineering, and operations in Columbus while investing in the technology and AI underpinning the TCO. The company is recruiting people who want startup pace and ownership without leaving the heartland to get it.

Open roles are at healiahealth.com/careers.

About Healia

Healia is a Columbus, Ohio, health tech company that builds health reimbursement arrangements (HRAs) for employers. Its Total Care Option (TCO) reduces benefit costs for employers and out-of-pocket costs for dual-income employees: when an employee enrolls in a spouse’s plan, Healia enables employers to reimburse the family’s out-of-pocket costs in full. Employers using Healia have provided $33M in additional coverage to their employees since its founding in 2021. Learn more at healiahealth.com.

Media Contact:
Kelsey LaBelle
[email protected]

SOURCE Healia

• Embedded digital dollar wallet volume up 263x year-on-year as stablecoins become core part of B2B payments infrastructure
• PSPs and fintechs have overtaken trading as the platform’s largest customer segment, signalling stablecoins‘ shift into mainstream payments

LONDON, July 28, 2026 — Businesses are increasingly replacing elements of traditional banking infrastructure with embedded stablecoin wallets, according to new proprietary data from BVNK. It shows embedded wallet volume increasing 263x during 2025 as companies adopted digital dollar accounts for global payments, enabling faster and lower-cost ways of holding, moving and converting value.

BVNK is a  leading provider of stablecoin infrastructure, processing more than $36 billion in annualised payment volume. The new data shows a shift toward businesses using stablecoins as “programmable dollars” that can operate outside of banking hours. Half of all BVNK’s transactions now take place outside standard banking hours, and after-hours transaction volume grew from 24% to 31% of total platform volume year-on-year, with volume rising from $2.65 billion to $8.83 billion. This suggests larger, higher-value business flows moving outside traditional banking windows as stablecoins shift from experimentation into infrastructure.

Enterprise adoption

BVNK’s data shows that stablecoin adoption is broadening beyond crypto-native firms. Payment service providers and fintechs have overtaken retail trading firms as BVNK’s largest customer segment, now accounting for 75% of platform volume, reflecting growing demand from companies rebuilding payment infrastructure around stablecoins.

Rather than simply using stablecoins for trading or treasury management, businesses are increasingly embedding digital dollar accounts directly into their products, creating an always-on payments layer alongside traditional banking infrastructure.

“Moving money across borders and between currencies has historically been slow and expensive. Businesses have relied on correspondent banking networks that can take days and add fees at every step.” said Chris Harmse, Co-Founder and Chief Business Officer at BVNK.

“Stablecoin wallets change that – they act as a proxy for a global dollar account: a single balance a business can hold, move and convert anywhere, instantly, without waiting on banking hours or intermediaries. Businesses are no longer experimenting with stablecoins, they’re rebuilding their payment infrastructure around them.”

BVNK’s 2025-2026 data showed stablecoin growth to be fastest in markets where dollar access has historically been constrained:

• Latin America pay-in volume grew 22x (led by Colombia, Argentina and Brazil);
• UK pay-in volume grew 19x, UK pay-out volume grew 5.17x
• APAC pay-out volume grew 3.4x
• Africa pay-out volume grew 4x

A practical playbook for launching wallets

Embedded stablecoin wallets enable businesses and individuals to send, receive, store, and convert stablecoins across borders and outside of the limits of traditional banking hours, and BVNK is already seeing customers build wallets into their infrastructure at scale.

Corporate payments provider, Corpay, which processes more than $12 billion in payments and $26 billion in foreign exchange each month across 145+ currencies, has integrated BVNK’s stablecoin wallets and settlement capabilities into its platform, giving customers 24/7 payment rails beyond the fixed hours of traditional banking infrastructure. The integration is also improving Corpay’s own capital efficiency, reducing reliance on pre-funded accounts and enabling faster movement of funds across its global footprint.

Global HR and compliance platform Ontop, fintech platform, Meow, and payment infrastructure provider TransferMate are among the other BVNK customers building similar capabilities into their own platforms.

To help businesses evaluate stablecoin wallets, BVNK has published a practical implementation guide covering compliance, infrastructure choices and deployment models. It also highlights use cases such as B2B payments, salary and gig payouts, P2P remittances and digital dollar accounts.

In addition to the guide, BVNK will be hosting a live Stablecoin Wallets 101 session on August 13 for teams evaluating stablecoin wallets, covering fundamentals and practical considerations for launch.

About BVNK: BVNK is the stablecoin-powered financial stack for enterprises. Build financial products. Unlock new markets. Move money in seconds across 130+ countries. One platform for every use case. Trusted by Worldpay, Deel, Corpay and Flywire. Processing billions annually. Learn more at BVNK.com.  

SOURCE BVNK

Twenty top early-stage venture capital firms co-host the second annual event, connecting the builders, backers, and buyers defining the future of enterprise AI

SAN FRANCISCO, July 28, 2026 — Connected Stack, the invitation-only summit bringing together the leaders shaping the future of enterprise AI, returns to San Francisco on Thursday, September 10, 2026.

Enterprise AI has moved from experimentation to large-scale deployment, and the questions that matter have changed with it. Now in its second year, Connected Stack convenes the  startup founders building the next generation of category-defining AI companies with early-stage investors and the enterprise executives deploying frontier AI. The day is designed to foster high-impact connections through founder flash talks, executive keynotes, and focused spotlight conversations.

The 2026 event is co-hosted by twenty of the industry’s leading venture firms: True Ventures, Accel, Addition, a16z, Ballistic Ventures, Battery Ventures, Conviction, Felicis, Forerunner, Greylock, GTM Capital, GV, Kleiner Perkins, Lightspeed, Menlo Ventures, Modern Technical Fund, Notable Capital, NVIDIA Inception Program, Redpoint, and Sound Ventures.

“We’ve watched this market move from demos to deployments to a much harder question: what does an enterprise actually trust with its data, workflows, and customers,” said Jon Callaghan, Co-founder and Managing Partner of True Ventures, a Connected Stack co-host. “The answer comes down to proof, and for the founders delivering it, this is the vintage of a lifetime. Get the builders, backers, and buyers in one room, and the whole industry moves faster than any one firm could push it.”

MTS, the always-on, timeline-native news network covering technology, AI, finance, and internet culture, will broadcast live from Connected Stack. Launched this spring with backing from a16z, MTS has quickly become one of the industry’s fastest-growing live media platforms. On September 10, it will turn its cameras to Connected Stack to cover the future of enterprise AI.

“We’re back at Connected Stack because last year’s room delivered – conversations that started there became pilots, partnerships, and deployments,” said Frédérique Dame, General Partner at GV, a returning co-host.

“The enterprise stack has been rebuilt many times; it’s only been reinvented once, and that’s now,” said Anish Acharya, General Partner at a16z, a returning co-host. “This is the group laying that architecture.”

“In enterprise AI, the companies that end up mattering most are usually the ones enterprises haven’t started buying from yet,” said Mamoon Hamid, Partner at Kleiner Perkins, a returning co-host. “This is the room where those introductions happen early — before the category leaders are obvious.”

Connected Stack is proudly supported by Lowenstein Sandler, Aduro Advisors, Attivo Partners, Goodwin Procter, and Silicon Valley Bank.

The full 2026 speaker lineup, including headlining keynotes, will be announced in August. Registration is limited. Learn more and request an invitation at connectedstack.ai.

About Connected Stack

Connected Stack is the premier gathering for enterprise AI, bringing together founders, operators, investors, and Fortune 1000 executives shaping the future of enterprise technology. Held annually in San Francisco, the event sits at the center of the AI startup ecosystem, creating meaningful connections between the builders of frontier AI and the enterprises deploying it at scale. Previous speakers have included Vercel CEO Guillermo Rauch, Anthropic Chief Commercial Officer Paul Smith, and Box CEO Aaron Levie. Learn more at connectedstack.ai.

SOURCE Connected Stack

Company’s new identity reflects the evolution of its proprietary bioaerogel platform while reaffirming its mission to restore human health through advanced biomaterials.

CLEVELAND, July 28, 2026 — Auxilium Health today announced that it is becoming Aeris Biosciences™. The name is new. The mission is not. Since its founding, the company has existed to restore human health, and that work continues with the same team and the same science, now matched by the resources and partners to pursue it faster, and a sharper sense of what it can become.

When the company started, the field knew it for its focus on soft-tissue healing. But its technology was never only about wounds. It is a platform: a new class of three-dimensional bioaerogels designed to inhibit bacterial colonization while guiding tissue regeneration, giving clinicians precise control over healing across wound repair, bone regeneration, and therapeutic delivery.

Aeris reflects what the company’s biomaterials are at their core. “Aer™” signals their foundation, their lightness, and spatial openness. “Biosciences” anchors the company in scientific rigor and clinical impact. Together they name a company built to work the way biology works: in three dimensions, where the architecture and surface of a material becomes the framework the body builds on.

The company believes materials must evolve with clinical standards. For too long, biomaterials have been passive, static surfaces that ask the body to heal around them. The standard of care keeps advancing, and the materials beneath it should advance too: sensing, responding, and actively shaping the environment in which healing happens. That conviction is the foundation of Aeris, and of a more resilient future, one in which healing is faster, safer, and more predictable for the patients and clinicians who depend on it.

“The name is new, but the promise behind it isn’t,” said Isaiah Kaiser, PhD, Founder and CEO of Aeris Biosciences™. “We built this company to restore human health, and every product we develop still answers that. Behind every wound, every implant, every difficult recovery is a person waiting to heal, and the people beside them waiting too. Aeris is our commitment to meet that moment with biomaterials that actively guide the body forward, and to keep building toward a future where healing is something clinicians can count on.”

About Aeris Biosciences

Aeris Biosciences, formerly Auxilium Health, develops a new class of bioaerogels that reduce the risk of bacterial colonization and guide tissue regeneration. Its Aer™ platform spans wound repair, bone regeneration, and localized therapeutic delivery, with a lead product advancing toward FDA clearance and clinical studies. Headquartered at the Cleveland Clinic’s Global Innovation Center, the company is supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster.

Learn more at https://aerisbio.com/ and follow Aeris Biosciences on LinkedIn.

Regeneration begins at the surface.

Media Contact
Lindsey Dinneen
Director of Marketing & Engagement
Project Medtech
Email: [email protected] 

SOURCE Aeris Biosciences

Three Companies, One Platform

The $10 million will fund two additional acquisitions, to be announced in coming months. Procode intends to follow the same playbook it used with The Auctus Group: acquire the best surgical billing companies and layer in Procode’s AI to drive better outcomes for surgeons:

• Procode: AI coding for surgery that automates the coding workflow from charge capture to submission, reduces coding-related denials, and fully captures reimbursements
• Procollect: An operating system for billing teams with native reporting, AI support and automation that reduces days in AR and accelerates reimbursements
• Auctus Provider App: An app that puts real-time financial data at Procode’s clients’ fingertips

“We’re on track to double The Auctus Group’s revenue and quintuple its EBITDA margin,” said Jeff Cripe, CEO of Procode. “That matters because we bill on contingency — we only get paid when our clients get paid — so our growth is proof our AI is putting more dollars in providers’ pockets, not just automating paperwork. Large health systems have had incredible technology companies innovating on their most pressing problems for years. We’re proud to innovate on behalf of the massive, long tail of RCM companies serving private practice surgeons.”

Procode AI Outperforms Professional Coders and Major LLMs

The retrospective comparative study published in PRS Global Open, “Artificial Intelligence for Automated CPT Coding in Plastic and Reconstructive Surgery Using a Fine-Tuned Hybrid LLM,” compared Procode AI’s fine-tuned hybrid LLM against OpenAI GPT-5, Google Gemini 2.5 Pro, Anthropic Claude Sonnet 4.5, and external professional auditors in reviewing operative reports at three different difficulty levels. A total of 120 case reports were analyzed (40 Easy difficulty, 40 Medium, 40 High).

Procode achieved 86.7% overall accuracy — more than double the best-performing LLM (OpenAI, 35.8%) and more than twice the accuracy of human auditors (42.5%). On easy cases, Procode was perfect: 100%. On the hardest cases (defined as including 4 or more CPT codes), it achieved 80% while general-purpose LLMs ranged from 5% to 12.5%.

“Our research shows that AI trained specifically for surgical coding can reliably outperform both humans and generic models,” said Kameron Rezzadeh, MD, FACS, cofounder and Chief Medical Officer of Procode. “That’s a step change in what billing accuracy looks like for private practice surgeons.”

Health Velocity Capital Leads Series A

Grant Blevins, Partner at Health Velocity Capital, said: “Over our careers, we have built deep expertise in revenue cycle management, developed relationships with exceptional billing practice owners, and grown increasingly convinced that this market is ready for a company that can finally deliver true end-to-end automation. Procode is uniquely positioned to do that by giving small billing practice owners a best-in-class AI strategy no traditional buyer can match, while preserving the specialty expertise that made their businesses valuable and building the category-defining RCM platform for private practice surgeons.”

About Procode Inc. Procode is an AI-powered RCM company for surgeons in private practice. Founded in 2024, Procode builds intelligent billing infrastructure that removes administrative burden and maximizes reimbursement, giving surgeons the freedom to focus on patient care. The company has raised $14 million in total venture funding and serves more than 350 plastic surgery and dermatology providers through its acquisition of The Auctus Group.

About Health Velocity Capital Health Velocity Capital invests exclusively in innovative healthcare software and services companies. The firm’s partners have more than 90 collective years as investors, entrepreneurs, and executives helping to finance and build innovative companies that created important new healthcare markets and that became market leaders, including successful companies such as Teladoc, Livongo, Change Healthcare, MDLive, Contessa Health, Headspace Health, Aspire Health, Zipari, IVX Health, Artera (fka Well Health), Compassus, Aperio, The Advisory Board Company, Healthways (Tivity Health), US Renal Care, Spero Health, OnShift, and many others. The firm counts among its limited partners many of the largest and most influential healthcare organizations in the country and current and former senior healthcare executives who collectively represent organizations that insure more than 175 million Americans, operate more than 1,000 hospitals, provide pharmacy and PBM services to everyone in the United States, and sell software to every major US health system.

Peer-reviewed research paper: 
https://journals.lww.com/prsgo/fulltext/10.1097/gox.0000000000007970~artificial-intelligence-for-automated-current-procedural

Download the App iOS: https://apps.apple.com/us/app/auctus-providers/id6751704100

Android: https://play.google.com/store/apps/details?id=com.procodeai.procodeaicompanion&hl=en_US

www.tryprocode.com | auctusgroupconsulting.com

SOURCE Procode Inc.

NEW YORK, July 28, 2026 — ProphetX, America’s first federally regulated sports-native prediction market, today announced the close of a $35 million fundraising round to accelerate its product development, boost liquidity across markets, and scale its B2B platform and partnerships.

The round drew participation from venture, sports, and proprietary trading firms, reflecting broad institutional confidence in ProphetX’s business model. The round was led by Parlay Capital and Data Point Capital, with participation from FDJ Ventures, Greenwave Ventures, Connexa Capital, Impellent Ventures, the Operating Group, and Sharp Alpha Advisors. Chicago Trading Company Ventures, Belvedere Trading, principals at White Swan Data, principals at Consolidated Trading, and Ematiq also made direct investments, signaling significant interest from the professional trading community in the emerging regulated prediction market space.

“On the heels of ProphetX’s recent nationwide launch and CFTC approval to operate as America’s first federally regulated sports-native prediction market, this raise gives us the fuel to meet the surging demand from both consumers and institutions to participate in this new asset class,” said ProphetX CEO and Co-Founder Dean Sisun. “Prediction markets are now a permanent fixture of the American financial landscape, and ProphetX intends to lead them.”

ProphetX previously operated as a sweepstakes platform, and following a successful FIFA World Cup as a federally regulated prediction market, has seen core KPIs including active users and assets on platform increase 50% in its first 30 days of operating. ProphetX is targeting a tripling of trading volume in 2026 driven by B2B partnerships, expanded institutional market coverage, and its proprietary Request for Quote (RFQ) Parlay Mechanism. This raise positions ProphetX to capture a significant share of the fast-growing B2B event contracts market.

Unlike sportsbooks, which are single-dealer models designed to profit when consumers lose, ProphetX is a true peer-to-peer exchange where users set their own prices, trade directly against one another, and pay a thin, transparent commission. ProphetX’s regulated market structure includes an RFQ Parlay Mechanism, which enables users to construct and price multi-event combinations directly with counterparties. The mechanism mirrors institutional trading protocols used in traditional financial markets, delivering flexibility, transparency, and competitive pricing to event-based contracts.

“We are excited to support Dean and the ProphetX team with additional capital to accelerate their next phase of growth as America’s first federally regulated, sports-native prediction market,” said Greg Buonocore, CEO and Managing Partner at Parlay Capital Holdings. “ProphetX is building the industry-leading infrastructure that will define how everyday Americans and institutional investors alike participate in sports prediction markets.”

“ProphetX has established itself as a pioneer in the prediction markets ecosystem, and we are thrilled to participate in this funding round,” said Scott Savitz, Founder and Managing Partner of Data Point Capital. “The company’s innovative approach, combined with its recent CFTC approval and increasing interest in event-based markets, positions it well for long-term growth. We look forward to supporting the team as they continue to execute on their vision.”

About ProphetX:
Founded in 2018, ProphetX is America’s first sports-native prediction market. The company is a regulated U.S. exchange for event-driven contracts, built on a sports-focused foundation and designed to expand across a broad range of event markets. Its mission is to create the world’s most trusted and innovative marketplace where anyone can participate in event outcomes.

Media Contact:
ProphetX Newsroom
[email protected]
https://www.prophetx.co/lobby/news

SOURCE ProphetX

Funding accelerates advancement of first-in-class non-invasive neuromodulation platform to transform the arc of stroke care in ICUs

ST. LOUIS, July 28, 2026 — Aurenar, developer of a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in intensive care unit (ICU) patients, today announced the close of an oversubscribed $5.7 million seed financing round, co-led by the Go Red for Women Venture Fund™, part of American Heart Association Ventures™ — the American Heart Association’s venture capital arm — and Solas BioVentures, with additional participation from BJC Health and Kaleida Capital. Proceeds from the investment round will fund continued advancement toward pivotal trials, including final device development, verification and validation (V&V) testing, and regulatory submissions to the U.S. Food and Drug Administration (FDA).

Aurenar’s V-Link™ platform, which recently received breakthrough device designation from the FDA, delivers transauricular vagus nerve stimulation (taVNS) to modulate the body’s inflammatory response to such conditions as subarachnoid hemorrhage (SAH). SAH alone accounts for roughly 7% of all strokes worldwide, leaving approximately 40% of survivors with permanent disability. Initially developed to respond to stroke and broader neurocritical-care challenges, V-Link has the potential to expand into additional high-impact indications in critically ill patients.

Inflammation is a central driver of the secondary injury that worsens outcomes in stroke, subarachnoid hemorrhage, and other critical illnesses. Modulating this cascade non-invasively in the ICU addresses a significant unmet need — and a meaningful opportunity to change recovery trajectories for many patients experiencing the most acute, high-risk conditions that also increase hospital costs.

The company was founded based on research from Dr. Eric Leuthardt, Dr. Anna Huguenard, and colleagues at Washington University School of Medicine in St. Louis. The randomized SAH trial they conducted demonstrated that taVNS reduced moderate-to-severe vasospasm by more than 40%, lowered pro-inflammatory cytokines, and improved functional outcomes. A companion analysis also showed a 20% drop in 30-day modifiable hospitalization costs directly linked to the method. A separate large-vessel occlusion (LVO) ischemic stroke trial showed consistent anti-inflammatory effects and a clean safety profile.

V-Link’s simple, wireless design makes it easier for neuro-intensive care physicians and ICU nursing staff to use the device without extensive training and supports faster onboarding and clinical adoption.

“We are excited to support Aurenar because stroke is a major cause of mortality and long-term disability in women, who face a disproportionately higher prevalence of subarachnoid hemorrhage. Their V-Link product promises to offer a pathway to improve recovery for all patients and especially for women who often experience higher rates of post-stroke complications,” said Tracy Warren, Sr. Managing Director, Go Red for Women Venture Fund, part of the American Heart Association Ventures family of funds. “The potential for use with other conditions that trigger the body’s inflammatory response, which also disproportionately affect women, makes V-Link the kind of scalable innovation our fund was created to accelerate.”

“This seed close marks a pivotal moment for Aurenar,” said Dr. Leuthardt, Founder and Chief Executive Officer of Aurenar and a professor of neurosurgery at WashU Medicine. “With the support of the Go Red for Women Venture Fund, Solas BioVentures, and our broader investor group, we are positioned to advance from early-stage neurotechnology to a pivotal-trial-ready company. Every dollar of this round is committed to milestones that help us improve outcomes for patients in the most critical moments of their care.”

“At WashU, we are reinforcing pathways that convert bold scientific ideas into real-world solutions,” said Doug Frantz, PhD, Vice Chancellor for Innovation and Commercialization, Washington University. “This neuromodulation platform is yet another example of the strength of WashU’s innovation ecosystem, and Dr. Leuthardt’s progress with Aurenar is bringing us closer to delivering meaningful advances to some of our most critically ill patients.”

About Aurenar
Aurenar is a company developing a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. The company’s transauricular vagus nerve stimulation (taVNS) device targets the body’s inflammatory response to improve outcomes, lower total cost of care, and transform critical care management. Beginning with the impacts of stroke, Aurenar’s platform is positioned to expand to address multiple high-acuity indications. Aurenar is headquartered in St. Louis, Missouri. Learn more at www.aurenar.com.

About Go Red Fund and American Heart Association Ventures
The Go Red for Women Venture Fund™ invests in market-driven solutions across a spectrum of heart health, brain health and related conditions to improve health for women. The Fund invests in early-stage companies whose products and services improve access, diagnosis and treatment for women. Through focused investment that translates science into action, the Go Red Fund is sparking real-world change and making a measurable difference in women’s lives.

The Go Red Venture Fund is part of American Heart Association Ventures, the venture capital platform of the American Heart Association.

About Solas BioVentures

Solas BioVentures is a venture capital firm investing in early- and development-stage biopharmaceutical, medical device, and digital health companies. Founded by physicians, scientists, and operators, the firm pairs deep clinical expertise and a patient-centric approach to funding technologies advancing the standard of care. Solas is headquartered in Chattanooga, Tennessee, with a presence in Research Triangle Park, North Carolina. Learn more at www.solasbio.com.

Solas BioVentures Management, LLC is an SEC-registered investment adviser. Registration does not imply a certain level of skill or training. For informational purposes only. Past performance is not indicative of future results. Investing involves risk, including the possibility of loss of principal. Learn more at https://adviserinfo.sec.gov/firm/summary/322344.

SOURCE Aurenar

Open-Source Malloy-Powered Platform Captures the Meaning of Enterprise Data, Delivers It As Context at Runtime to AI Agents, APIs, Analytics Tools and More

BOULDER, Colo., July 28, 2026 — Credible Data, the trusted business context engine for enterprise AI, today announced a significant acceleration in the scale-up of its platform following a $10 million seed round from Gradient, SignalFire and K5 Global, along with angel investors including G2 cofounder & CEO Godard Abel, pandas creator and Composed Ventures General Partner Wes McKinney, Snowplow Analytics CEO and co-founder Alex Dean, SV Angel and others. Built on Malloy, an open-source semantic modeling language, Credible’s platform turns organization-specific governed metrics, definitions, entities, and relationships into executable business context that AI agents and applications can query, reuse and trust at scale.

Enterprises have made rapid progress giving AI agents access to unstructured and semi-structured data through documents and knowledge bases. Much of the data that actually runs the business, though, still lives in data warehouses such as Google BigQuery, Snowflake or Postgres. For AI to use this structured data reliably, it needs more than access to rows and columns; it needs the governed business meaning behind the data, including how metrics are defined, how entities relate, which rules apply, and who is allowed to see what. Without that business context, AI agents can produce inconsistent or incorrect answers from the same underlying data, undermining enterprise trust in AI.

Credible Data’s context engine solves this problem by analyzing how an enterprise actually uses its data – informed by real queries and edge cases surfaced during use – to generate a universal, governable semantic model of organization-specific business context using Malloy. Credible Data’s platform makes all of this context available to AI agents, analytics tools and other systems at runtime, enabling organizations to achieve trusted results from every element of their tech stacks while avoiding vendor lock-in and ensuring industry-leading flexibility and agility.

Credible Data CEO and founder Kyle Nesbit said, “Every organization attaches its own meaning to its data — even a term as familiar as ‘revenue’ can mean completely different things from one company to the next. AI can’t be trusted with enterprise data until it understands that meaning. The winners in enterprise AI will be the ones who deliver their data’s meaning as context wherever decisions get made, without locking themselves into a single vendor’s stack. That’s what we’ve built at Credible Data.”

Credible Data takes Malloy’s semantic modeling foundation to enterprise scale, adding the security, role-based access controls, governance, reliability, auditability, and operational safeguards required for mission-critical analytics and high-volume agentic AI workloads.

Gradient General Partner Zach Bratun-Glennon said, “Existing data warehouse and pipeline solutions were never built for AI. As enterprises rush to deploy AI throughout their organizations, they are finding their ability to trust this new technology undermined by conflicting outputs stemming from a lack of consistent meaning applied to their data. Credible Data has built a platform that solves this challenge with unprecedented agility and flexibility, and which we believe will be fundamental in finally achieving trustworthy AI for enterprises.”

Credible Data has assembled an exceptional team with deep industry expertise to pursue its mission. Nesbit previously led Business Intelligence and Data Analytics at Google Cloud and spearheaded Looker’s integration into that platform; prior to that he led Forward Deployed Engineering at Gradient. Additionally, the company’s Head of Product, James Swirhun, spent eight years at Google working on AI/ML products including Gemini; prior to that he was a consultant at Bain & Company.

Peter Nummerdor, SVP of Product for VideoAmp, a Credible Data customer, said, “Our planning and measurement drives decisions by some of the largest companies in the advertising industry, so every insight our AI gives has to be consistent, defensible and grounded in fact. Credible gives our AI systems the same governed understanding of our metrics that our best analysts carry in their heads. That’s what moved us from experimenting with AI to putting it in front of customers with confidence.”

About Credible Data
Credible Data is the engine for trusted business context on enterprise data. Built on Malloy, an open-source semantic modeling language, Credible turns governed metrics, definitions, entities, and relationships into executable context that AI agents and applications can query, reuse, and trust.

Media Contact
Chris Clemens
Nexios Communications Strategies
[email protected]

SOURCE Credible Data

REDWOOD CITY, Calif., July 28, 2026 — Array Labs has raised $21 million in an oversubscribed strategic investment round, anchored by Mitsubishi Electric Corporation, with continued participation from Catapult Ventures, Kompas VC, and Y Combinator. Array Labs and Mitsubishi Electric have also entered into a partnership to develop and bring to market satellite-based maritime and aircraft tracking services for defense and security customers in the Asia Pacific Region.

This investment follows Array’s Series A fundraise, announced in January 2026.

Array Labs and Mitsubishi Electric Partnership

Mitsubishi Electric is one of Japan’s largest defense and aerospace contractors, supplying advanced electronics, radar, and satellite systems to the Japanese Ministry of Defense for over half a century. In February 2026, it was awarded a contract to develop and manufacture Japan’s next-generation defense satellite system.

This partnership brings together Array’s transformative approach with Mitsubishi Electric’s satellite system development capabilities, manufacturing infrastructure, and established relationships with defense and government customers across the Asia-Pacific region. Together, Array and Mitsubishi Electric will bring moving object detection and tracking services to defense and security customers.

“We are very pleased to collaborate with Array Labs, which aims to demonstrate its game-changing AMTI technology. By combining the technological capabilities and maximizing the synergies of our two companies, we expect to strengthen our ability to respond comprehensively to customer needs in the security field, “said Masahiko Arai, Executive Officer, Company President, Defense and Space Systems, Mitsubishi Electric Corporation.

“Mitsubishi Electric Corporation’s deep mission insights and defense relationships across Asia-Pacific make them an ideal partner. We’re excited to work together to turn space-based AMTI into an operational reality, helping humanity better understand the physical world,” said Andrew Peterson, CEO and cofounder of Array Labs.

Array Labs has validated its core formation flying and multistatic technology, and earned competitive research and development contracts with DARPA, the U.S. Navy, and the U.S. Air Force.

About Array Labs
Array Labs is building a new way to understand the physical world. Based in Silicon Valley and backed by Y Combinator, Catapult Ventures, Kompas VC, and Washington Harbour Partners, the company is preparing to launch the world’s first coordinated fleet of radar satellites to deliver high-resolution, continuously updated intelligence about the Earth’s terrain, infrastructure, and activity, operating day or night, through clouds, anywhere on the planet. For more information, visit www.arraylabs.io.

About Mitsubishi Electric Corporation
Mitsubishi Electric Corporation is one of Japan’s largest and most established defense and aerospace contractors, supplying advanced electronics, radar, and satellite systems to the Japanese Ministry of Defense for over half a century. Headquartered in Tokyo, the company operates across defense, aerospace, energy, infrastructure, and industrial applications, and maintains partnerships with major defense primes across the United States and Europe. For more information, visit www.mitsubishielectric.com.

Press & Media Contact

Hannah Sachs
Director of External Affairs
Email: [email protected]

SOURCE Array Labs, Inc.